Compare iShares Global Clean Energy ETF (ICLN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares Global Clean Energy ETF trades at $17.28 (market cap $2.30B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.31B). The key difference: iShares Global Clean Energy ETF and Recursion Pharmaceuticals Inc are close in size by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| ICLN | RXRX | |
|---|---|---|
Market Cap | $2.30B | $2.31B |
Volume | 3,661,617 | 40,478,768 |
52-Week High | $23.75 | $6.79 |
52-Week Low | $15.78 | $2.84 |
Typical Hold Time | 87 Days | 22 Days |
Sector | — | Health |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.31, down 1.31% with a bearish technical signal from moving averages. The ETF faces volatility with clean energy exposure showing deeper drawdowns compared to traditional energy peers. Recent news highlights competitive pressure from fossil fuel ETFs delivering stronger returns and lower fees, though geopolitical tensions are accelerating global renewable energy adoption.
The outlook remains challenged by high expense ratios and sector volatility, but long-term growth potential exists from global energy transition trends. Key risks include competitive pressure from traditional energy and execution challenges in renewable adoption timelines.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
